AVEO Pharmaceuticals, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael P. Bailey
- Full Time Employees
- 114
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 30 Winter Street Boston MA United States of America 02108
- IPO Date
- Mar 12, 2010
- CIK
- 0001325879
- Website
- aveooncology.com
- Similar Companies
- Business
- AVEO Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company that primarily discovers, develops, and commercializes cancer therapeutics. The company's core product portfolio centers around FOTIVDA (tivozanib), an oral next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) approved by the U.S. Food and Drug Administration (FDA) in March 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO also develops a pipeline of investigational IgG1 monoclonal antibodies including ficlatuzumab (targeting head and neck cancer), AV-380 (targeting cancer-related cachexia), AV-203, and AV-353, aimed at addressing unmet needs in various oncologic indications such as solid tumors and hematologic malignancies. The company leverages strategic collaborations and partnerships to advance its product candidates and pipeline programs globally. Founded in 2001 and headquartered in Cambridge, Massachusetts, AVEO operates primarily in the United States with ongoing efforts to commercialize its therapies and expand its oncology portfolio. A significant recent development in AVEO's corporate history is its acquisition by LG Chem, completed in early 2023 in a transaction valued at approximately $571 million. This all-cash acquisition integrates AVEO into LG Chem's life sciences division, bolstering LG Chem’s position in the oncology sector and enabling AVEO to expand its clinical and commercial footprint in North America and beyond. The merger supports broader R&D investment exceeding $300 million in the integrated operation and further capital commitments over five years, targeting advancements in oncology drug development and commercialization. AVEO’s strategic focus includes the advancement of FOTIVDA for novel immuno-oncology combinations and broader indications, alongside internal clinical development of monoclonal antibodies addressing specific cancer types and conditions such as cachexia. Recent updates underscore the company's commitment to growth via clinical innovation, new product launches, and leveraging LG Chem’s resources to amplify its presence in global oncology markets. The company maintains a policy of purposeful acquisitions and licensing agreements to efficiently develop its pipeline and meet critical oncology patient needs. In summary, AVEO Pharmaceuticals functions as a commercial-stage oncology biopharmaceutical entity specializing in targeted cancer therapies and monoclonal antibody development, with a strengthened strategic profile following its acquisition by LG Chem. Its main marketed product is FOTIVDA for advanced RCC, and its development pipeline includes several monoclonal antibodies for solid tumors and cancer-related cachexia. The 2023 LG Chem acquisition marks a major strategic milestone enabling expansion and increased R&D investment targeted at innovative cancer treatments in North America and globally. All data are current as of late 2025 and incorporate recent corporate activities, product developments, and strategic alliances publicly disclosed by AVEO and LG Chem.
CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist
AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
4 Drug Stocks That More Than Doubled This Year
Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?
AVEO Oncology (AVEO): Strong Industry, Solid Earnings Estimate Revisions
What Makes AVEO Pharmaceuticals (AVEO) a Strong Momentum Stock: Buy Now?
AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates
AVEO Pharmaceuticals (AVEO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
AVEO Oncology (AVEO) to Report Q3 Earnings: Is a Beat in Store?
Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?
Why LG Chem Is Buying AVEO Oncology (AVEO) For $566 Million
Biopharma Stock Soaring on Buyout News
Aveo Stock Continues Its Bullish Run After Snagging $566 Million LG Chem Buyout
What Is Going on With AVEO Pharmaceuticals (AVEO) Stock Today?
3 Breakout Stocks to Keep an Eye on for Solid Returns
Is AVEO Pharmaceuticals (AVEO) Stock Outpacing Its Medical Peers This Year?
New Analysts Initiate Coverage: 3 Top-Ranked Stocks to Buy
Is AVEO Pharmaceuticals (AVEO) Outperforming Other Medical Stocks This Year?